Johnson & Johnson Debt to Equity Ratio 2011-2025 | JNJ
Current and historical debt to equity ratio values for Johnson & Johnson (JNJ) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Johnson & Johnson debt/equity for the three months ending September 30, 2025 was 0.50.
| Johnson & Johnson Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2025-09-30 | $113.54B | $79.28B | 1.43 |
| 2025-06-30 | $114.92B | $78.47B | 1.46 |
| 2025-03-31 | $115.56B | $78.11B | 1.48 |
| 2024-12-31 | $108.61B | $71.49B | 1.52 |
| 2024-09-30 | $108.13B | $70.16B | 1.54 |
| 2024-06-30 | $109.55B | $71.54B | 1.53 |
| 2024-03-31 | $101.95B | $70.02B | 1.46 |
| 2023-12-31 | $98.78B | $68.77B | 1.44 |
| 2023-09-30 | $94.83B | $71.23B | 1.33 |
| 2023-06-30 | $115.28B | $76.41B | 1.51 |
| 2023-03-31 | $125.10B | $70.87B | 1.77 |
| 2022-12-31 | $110.57B | $76.80B | 1.44 |
| 2022-09-30 | $100.53B | $74.60B | 1.35 |
| 2022-06-30 | $101.37B | $76.36B | 1.33 |
| 2022-03-31 | $103.65B | $74.71B | 1.39 |
| 2021-12-31 | $108.00B | $74.02B | 1.46 |
| 2021-09-30 | $108.96B | $70.27B | 1.55 |
| 2021-06-30 | $106.86B | $69.58B | 1.54 |
| 2021-03-31 | $106.72B | $65.83B | 1.62 |
| 2020-12-31 | $111.62B | $63.28B | 1.76 |
| 2020-09-30 | $106.22B | $64.47B | 1.65 |
| 2020-06-30 | $95.40B | $62.98B | 1.52 |
| 2020-03-31 | $93.72B | $61.29B | 1.53 |
| 2019-12-31 | $98.26B | $59.47B | 1.65 |
| 2019-09-30 | $97.31B | $58.21B | 1.67 |
| 2019-06-30 | $94.33B | $60.79B | 1.55 |
| 2019-03-31 | $91.07B | $58.96B | 1.55 |
| 2018-12-31 | $93.20B | $59.75B | 1.56 |
| 2018-09-30 | $91.08B | $64.63B | 1.41 |
| 2018-06-30 | $92.48B | $62.89B | 1.47 |
| 2018-03-31 | $93.37B | $63.26B | 1.48 |
| 2017-12-31 | $97.14B | $60.16B | 1.62 |
| 2017-09-30 | $81.68B | $73.98B | 1.10 |
| 2017-06-30 | $80.89B | $71.92B | 1.13 |
| 2017-03-31 | $74.58B | $70.34B | 1.06 |
| 2016-12-31 | $70.79B | $70.42B | 1.01 |
| 2016-09-30 | $67.60B | $72.77B | 0.93 |
| 2016-06-30 | $67.34B | $72.47B | 0.93 |
| 2016-03-31 | $63.58B | $72.65B | 0.88 |
| 2015-12-31 | $62.26B | $71.15B | 0.88 |
| 2015-09-30 | $61.71B | $71.55B | 0.86 |
| 2015-06-30 | $60.91B | $71.13B | 0.86 |
| 2015-03-31 | $60.71B | $67.88B | 0.89 |
| 2014-12-31 | $60.61B | $69.75B | 0.87 |
| 2014-09-30 | $55.51B | $76.59B | 0.73 |
| 2014-06-30 | $57.15B | $78.05B | 0.73 |
| 2014-03-31 | $56.75B | $76.58B | 0.74 |
| 2013-12-31 | $58.63B | $74.05B | 0.79 |
| 2013-09-30 | $57.13B | $69.80B | 0.82 |
| 2013-06-30 | $54.66B | $69.67B | 0.79 |
| 2013-03-31 | $54.68B | $66.86B | 0.82 |
| 2012-12-31 | $56.52B | $64.83B | 0.87 |
| 2012-09-30 | $55.19B | $63.76B | 0.87 |
| 2012-06-30 | $55.32B | $60.43B | 0.92 |
| 2012-03-31 | $54.83B | $61.37B | 0.89 |
| 2011-12-31 | $56.56B | $57.08B | 0.99 |
| 2011-09-30 | $50.29B | $61.53B | 0.82 |
| 2011-06-30 | $49.98B | $62.13B | 0.80 |
| 2011-03-31 | $48.29B | $59.86B | 0.81 |
| 2010-12-31 | $46.33B | $56.58B | 0.82 |
| 2010-09-30 | $40.96B | $57.29B | 0.72 |
| 2010-06-30 | $39.45B | $52.85B | 0.75 |
| 2010-03-31 | $40.53B | $52.91B | 0.77 |
| 2009-12-31 | $44.09B | $50.59B | 0.87 |
| 2009-09-30 | $41.17B | $50.38B | 0.82 |
| 2009-06-30 | $41.19B | $46.25B | 0.89 |
| 2009-03-31 | $42.31B | $43.79B | 0.97 |
| 2008-12-31 | $42.40B | $42.51B | 1.00 |
| 2008-09-30 | $41.99B | $45.73B | 0.92 |
| 2008-06-30 | $41.68B | $46.44B | 0.90 |
| 2008-03-31 | $40.37B | $45.63B | 0.89 |
| 2007-12-31 | $37.64B | $43.32B | 0.87 |
| 2007-09-30 | $35.09B | $43.57B | 0.81 |
| 2007-06-30 | $31.56B | $43.12B | 0.73 |
| 2007-03-31 | $32.14B | $40.93B | 0.79 |
| 2006-12-31 | $31.24B | $39.32B | 0.79 |
| 2006-09-30 | $20.67B | $40.57B | 0.51 |
| 2006-06-30 | $20.25B | $40.74B | 0.50 |
| 2006-03-31 | $21.01B | $41.12B | 0.51 |
| 2005-12-31 | $20.15B | $38.71B | 0.52 |
| 2005-09-30 | $19.73B | $36.85B | 0.54 |
| 2005-06-30 | $19.38B | $35.17B | 0.55 |
| 2005-03-31 | $20.79B | $33.65B | 0.62 |
| 2004-12-31 | $21.50B | $31.81B | 0.68 |
| 2004-09-30 | $20.58B | $31.51B | 0.65 |
| 2004-06-30 | $20.12B | $30.05B | 0.67 |
| 2004-03-31 | $20.37B | $28.49B | 0.72 |
| 2003-12-31 | $21.39B | $26.87B | 0.80 |
| 2003-09-30 | $20.92B | $25.74B | 0.81 |
| 2003-06-30 | $21.22B | $24.44B | 0.87 |
| 2003-03-31 | $17.96B | $24.04B | 0.75 |
| 2002-12-31 | $17.86B | $22.70B | 0.79 |
| 2002-09-30 | $16.58B | $22.09B | 0.75 |
| 2002-06-30 | $16.46B | $21.89B | 0.75 |
| 2002-03-31 | $14.57B | $23.72B | 0.61 |
| 2001-12-31 | $14.26B | $24.23B | 0.59 |
| 2001-09-30 | $13.32B | $23.73B | 0.56 |
| 2001-06-30 | $13.39B | $22.71B | 0.59 |
| 2001-03-31 | $11.78B | $20.09B | 0.59 |
| 2000-12-31 | $13.85B | $20.40B | 0.68 |
| 2000-09-30 | $12.30B | $18.49B | 0.67 |
| 2000-06-30 | $12.33B | $17.98B | 0.69 |
| 2000-03-31 | $12.81B | $17.15B | 0.75 |
| 1999-12-31 | $12.95B | $16.21B | 0.80 |
| 1999-09-30 | $12.72B | $15.38B | 0.83 |
| 1999-06-30 | $12.38B | $14.74B | 0.84 |
| 1999-03-31 | $12.52B | $14.22B | 0.88 |
| 1998-12-31 | $12.62B | $13.59B | 0.93 |
| 1998-09-30 | $9.40B | $13.94B | 0.67 |
| 1998-06-30 | $9.00B | $13.31B | 0.68 |
| 1998-03-31 | $9.11B | $12.81B | 0.71 |
| 1997-12-31 | $9.09B | $12.36B | 0.74 |
| 1997-09-30 | $9.50B | $12.18B | 0.78 |
| 1997-06-30 | $9.28B | $11.72B | 0.79 |
| 1997-03-31 | $9.45B | $11.17B | 0.85 |
| 1996-12-31 | $9.17B | $10.84B | 0.85 |
| 1996-09-30 | $9.23B | $10.68B | 0.87 |
| 1996-06-30 | $9.07B | $10.24B | 0.89 |
| 1996-03-31 | $9.11B | $9.83B | 0.93 |
| 1995-12-31 | $8.83B | $9.05B | 0.98 |
| 1995-09-30 | $8.78B | $8.91B | 0.99 |
| 1995-06-30 | $8.83B | $8.56B | 1.03 |
| 1995-03-31 | $8.76B | $7.88B | 1.11 |
| 1994-12-31 | $8.55B | $7.12B | 1.20 |
| 1994-09-30 | $7.84B | $6.99B | 1.12 |
| 1994-06-30 | $6.82B | $6.62B | 1.03 |
| 1994-03-31 | $6.73B | $6.09B | 1.11 |
| 1993-12-31 | $6.67B | $5.57B | 1.20 |
| 1993-09-30 | $6.71B | $5.70B | 1.18 |
| 1993-06-30 | $6.51B | $5.71B | 1.14 |
| 1993-03-31 | $6.42B | $5.54B | 1.16 |
| 1992-12-31 | $6.71B | $5.17B | 1.30 |
| 1992-09-30 | $5.84B | $5.97B | 0.98 |
| 1992-06-30 | $5.53B | $5.71B | 0.97 |
| 1992-03-31 | $4.72B | $5.74B | 0.82 |
| 1991-12-31 | $4.89B | $5.63B | 0.87 |
| 1991-09-30 | $4.50B | $5.36B | 0.84 |
| 1991-06-30 | $4.37B | $5.06B | 0.86 |
| 1991-03-31 | $4.37B | $4.93B | 0.89 |
| 1990-12-31 | $4.61B | $4.90B | 0.94 |
| 1990-09-30 | $4.81B | $4.74B | 1.01 |
| 1990-06-30 | $4.62B | $4.55B | 1.02 |
| 1990-03-31 | $4.35B | $4.29B | 1.02 |
| 1989-12-31 | $3.77B | $4.15B | 0.91 |
| 1989-09-30 | $3.68B | $3.93B | 0.94 |
| 1989-06-30 | $3.85B | $3.75B | 1.03 |
| 1989-03-31 | $3.74B | $3.62B | 1.03 |
| 1988-12-31 | $3.62B | $3.50B | 1.03 |
| 1988-09-30 | $3.40B | $3.51B | 0.97 |
| 1988-06-30 | $3.49B | $3.60B | 0.97 |
| 1988-03-31 | $3.30B | $3.67B | 0.90 |
| 1987-12-31 | $3.06B | $3.49B | 0.88 |
| 1987-09-30 | $3.44B | $3.29B | 1.05 |
| 1987-06-30 | $3.34B | $3.16B | 1.06 |
| 1987-03-31 | $3.22B | $3.02B | 1.07 |
| 1986-12-31 | $3.05B | $2.82B | 1.08 |
| 1985-12-31 | $1.74B | $3.35B | 0.52 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $472.053B | $88.821B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $969.283B | 46.62 |
| AbbVie (ABBV) | United States | $410.669B | 24.59 |
| Roche Holding AG (RHHBY) | Switzerland | $286.026B | 0.00 |
| Novartis AG (NVS) | Switzerland | $277.276B | 14.70 |
| Merck (MRK) | United States | $230.630B | 10.74 |
| Novo Nordisk (NVO) | Denmark | $215.481B | 12.63 |
| Pfizer (PFE) | United States | $142.484B | 7.83 |
| Sanofi (SNY) | France | $128.030B | 12.30 |
| Bayer (BAYRY) | Germany | $32.184B | 5.65 |
| Innoviva (INVA) | United States | $1.664B | 8.33 |